What happened
Veru (NASDAQ: VERU), a high-flying cancer and COVID-19 stock, is in full-on retreat mode today. Specifically, the biotech's shares were down by a hefty 17%, on average volume, as of 12:38 p.m. ET Tuesday afternoon.
What's causing investors to head for the exits today? The good news is that Veru didn't release any material news today, so its value proposition hasn't suddenly changed. The bad news is that investors appear to be profit-taking across the varied healthcare landscape today in response to the Federal Reserve's plans to continue raising interest rates in 2023.
So what
Thanks to the sizable commercial potential of its severe COVID-19 therapy known as sabizabulin, Veru's share price shot up by an astronomical 198% at its peak earlier this year. Veru thus stands out as a top target for profit-taking, especially in this increasingly risk-averse environment.
Keeping with this theme, most of the top-performing healthcare stocks in 2022, such as Axsome Therapeutics and Siga Technologies, are also deep in the red today. Healthcare investors don't seem willing to take any chances with additional rake hikes on the horizon.
Now what
Is this double-digit drop in Veru's share price a buying opportunity? I think so. Sabizabulin should fill a critical gap in the care for hospitalized COVID-19 patients. As a result, the drug should garner a healthy level of sales if it does indeed get approved for this indication by the U.S. Food and Drug Administration. Therefore, bargain hunters may want to take advantage of this weakness in Veru's shares today.
10 stocks we like better than Veru, Inc
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Veru, Inc wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of August 17, 2022
George Budwell has positions in Axsome Therapeutics. The Motley Fool has positions in and recommends Axsome Therapeutics. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
